Review of NICE Technology Appraisal Guidance No. 185; Trabectedin for the treatment of advanced metastatic soft tissue sarcoma 

The Institute was proposing that the guidance should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

TA185 will therefore be moved to the static guidance list, however if NICE is notified of a significant change to the evidence base at any stage in the future then this could trigger further consideration and another review proposal.

April 2013